» Articles » PMID: 36014945

Testosterone Deficiency As One of the Major Endocrine Disorders in Chronic Kidney Disease

Overview
Journal Nutrients
Date 2022 Aug 26
PMID 36014945
Authors
Affiliations
Soon will be listed here.
Abstract

Reduced testosterone concentration is nowadays thought to be one of the main endocrine disorders in chronic kidney disease (CKD). It is caused by the dysfunction of the hypothalamic-pituitary-gonadal axis. The role of testosterone is multifactorial. Testosterone is responsible not only for reproductive processes, but it is a hormone which increases bone and muscle mass, improves lipid profile, insulin sensitivity, erythropoiesis, reduces blood pressure, and ameliorates mood and perception. The implications of hypogonadism in CKD are infertility and loss of libido, reduction of muscle mass and strength, disorders in bone mineralization, the development of sarcopenia and protein energy wasting (PEW), progression of atherosclerosis, increased visceral adiposity, insulin resistance, and anaemia. Reduced testosterone serum concentrations in CKD are associated with increased mortality rate. Testosterone supplementation improves sexual functions, reduces the level of inflammatory markers and blood pressure, stimulates muscle protein synthesis, improves insulin sensitivity and lipid profile, and increases muscle mass, bone mineral density, and haemoglobin concentration. It positively affects mood and well-being. The modes of testosterone supplementation are intramuscular injections, subcutaneous pellets, and percutaneous methods-patches and gels. Successful kidney transplantation may improve gonadal function and testosterone production, however, half of men with low testosterone concentrations before kidney transplantation do not restore hormonal function.

Citing Articles

Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction.

Abidor E, Achkar M, Al Saidi I, Lather T, Jdaidani J, Agarwal A J Clin Med. 2025; 14(2).

PMID: 39860649 PMC: 11765848. DOI: 10.3390/jcm14020643.


Regulation of the blood-brain barrier function by peripheral cues in health and disease.

Devraj K, Kulkarni O, Liebner S Metab Brain Dis. 2024; 40(1):61.

PMID: 39671124 PMC: 11645320. DOI: 10.1007/s11011-024-01468-8.


Kidney disease and reproductive health.

Smith P, Sarris I, Clark K, Wiles K, Bramham K Nat Rev Nephrol. 2024; 21(2):127-143.

PMID: 39501029 DOI: 10.1038/s41581-024-00901-6.


Association between the weight-adjusted-waist index and testosterone deficiency in adult males: a cross-sectional study.

Wang P, Li Q, Wu L, Yu X, Zheng Y, Liu J Sci Rep. 2024; 14(1):25574.

PMID: 39462140 PMC: 11513048. DOI: 10.1038/s41598-024-76574-9.


Sexual dimorphism in a mouse model of Friedreich's ataxia with severe cardiomyopathy.

Salinas L, Montgomery C, Figueroa F, Thai P, Chiamvimonvat N, Cortopassi G Commun Biol. 2024; 7(1):1250.

PMID: 39363102 PMC: 11449905. DOI: 10.1038/s42003-024-06962-4.


References
1.
Nixon A, Bampouras T, Pendleton N, Woywodt A, Mitra S, Dhaygude A . Frailty and chronic kidney disease: current evidence and continuing uncertainties. Clin Kidney J. 2018; 11(2):236-245. PMC: 5888002. DOI: 10.1093/ckj/sfx134. View

2.
Kapoor D, Goodwin E, Channer K, Jones T . Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006; 154(6):899-906. DOI: 10.1530/eje.1.02166. View

3.
Maggi M, Wu F, Jones T, Jackson G, Behre H, Hackett G . Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME). Int J Clin Pract. 2016; 70(10):843-852. DOI: 10.1111/ijcp.12876. View

4.
Bhasin S, Singh A, Mac R, Carter B, Lee M, Cunningham G . Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003; 24(3):299-311. DOI: 10.1002/j.1939-4640.2003.tb02676.x. View

5.
Middleton T, Turner L, Fennell C, Savkovic S, Jayadev V, Conway A . Complications of injectable testosterone undecanoate in routine clinical practice. Eur J Endocrinol. 2015; 172(5):511-7. DOI: 10.1530/EJE-14-0891. View